No I am not. You are conflating the issue of a statistical test by a third party contractor with a judgment or analysis of data by the company or FDA. A third party statistician hired by the Company gives a report to the Company that the trial did not meet its Primary Endpoint. That is a materially adverse event in a Phase 3 trial of a Company's lead drug any "reasonable investor" would think so, that is the test. Another such material event would be a fatal AE attributed to the drug.
News 
Market Data 
Discover 
